Trial Profile
QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs PSI 938 (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms QUANTUM
- Sponsors Gilead Sciences
- 07 Jan 2014 As per ClinicalTrials.gov record timeframe of primary endpoint is changed from week 24 to 12; PSI-938, PSI-938+sofosbuvir, PSI-938+sofosbuvir+ribavirin 12 weeks arm group is removed and Re-treatment: sofosbuvir+ribavirin (24 weeks) arm group added.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2012 Planned end date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.